Burning Rock Biotech (NASDAQ:BNR) Posts Quarterly Earnings Results
Burning Rock Biotech (NASDAQ:BNR) reported a quarterly earnings per share (EPS) of ($0.26), with a negative return on equity of 23.61% and a negative net margin of 26.04%. The stock traded up $2.07 to $18.10, with a market cap of $194.76 million. Analysts have mixed ratings, with a recent upgrade to 'buy' by Wall Street Zen, despite an average 'sell' rating. The company specializes in cancer therapy selection tests in China.
Burning Rock Biotech (NASDAQ:BNR - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.26) EPS for the quarter, Zacks reports. Burning Rock Biotech had a negative net margin of 26.04% and a negative return on equity of 23.61%.
Get Burning Rock Biotech alerts:
Burning Rock Biotech Price Performance
- What Are Utility Stocks? An Overview of the Utilities Sector
BNR traded up $2.07 during midday trading on Thursday, reaching $18.10. 17,549 shares of the company's stock were exchanged, compared to its average volume of 31,103. Burning Rock Biotech has a 1-year low of $2.18 and a 1-year high of $18.51. The stock has a market capitalization of $194.76 million, a PE ratio of -9.52 and a beta of 1.11. The business's 50-day moving average price is $10.31 and its 200 day moving average price is $6.92.
Analyst Ratings Changes
Several research firms recently weighed in on BNR. Weiss Ratings restated a "sell (d-)" rating on shares of Burning Rock Biotech in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Burning Rock Biotech to a "buy" rating in a report on Saturday, November 1st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Burning Rock Biotech presently has an average rating of "Sell".
View Our Latest Research Report on Burning Rock Biotech
About Burning Rock Biotech
(Get Free Report)Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
See Also
- Five stocks we like better than Burning Rock Biotech
- Trading Stocks: RSI and Why it's Useful
- NVIDIA Just Proved the AI Boom Is Bigger Than Anyone Thought
- What is Put Option Volume?
- Why Target Stock May Keep Falling Despite a 5% Dividend Yield
- The How And Why of Investing in Oil Stocks
- Is Tesla Setting Up for a Year-End Rebound—or a Collapse?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Burning Rock Biotech Right Now?
Before you consider Burning Rock Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Burning Rock Biotech wasn't on the list.
While Burning Rock Biotech currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
